Last reviewed · How we verify
TCI378
TCI378, marketed by National Taiwan University Hospital, is a therapeutic agent with a key composition patent expiring in 2028. The drug's mechanism of action involves interacting with a specific biological target, providing a unique therapeutic effect that distinguishes it in the market. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | TCI378 |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Evaluation of TCI378 and TCI507 Probiotics on Weight-lowering Efficacy in Adults (NA)
- The Evaluation of TCI378 and TCI507 Probiotics on Weight-lowering Efficacy in Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TCI378 CI brief — competitive landscape report
- TCI378 updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI